Drug Profile


Alternative Names: Cipralex; Entact; Lexapro; LU-26054; MLD-55; S-citalopram; Seroplex; Sipralex; Sipralexa

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Developer Allergan; Forest Laboratories; Lundbeck A/S; Mochida Pharmaceutical
  • Class Antidepressants; Anxiolytics; Benzofurans; Fluorobenzenes; Nitriles; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 20 Nov 2015 Registered for Social phobia in Japan (PO)
  • 01 May 2015 Lundbeck A/S terminates a phase II/III trial for Major depressive disorder in Switzerland (NCT01219686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top